Literature DB >> 20888030

Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension.

Agnès Tournier1, Denis Wahl, Ari Chaouat, Jean-Pierre Max, Véronique Regnault, Thomas Lecompte, François Chabot.   

Abstract

INTRODUCTION: Pathogenesis of idiopathic pulmonary arterial hypertension (iPAH) includes endothelial dysfunction and in situ thrombosis. A hypercoagulable state has also been postulated but never demonstrated. Our objective was to determine whether patients with iPAH had a hypercoagulable state using calibrated automated thrombography (CAT), a new tool to phenotype coagulation in vitro. PATIENTS AND METHODS: 16 patients with iPAH and 29 controls were studied. In vitro platelet dependent coagulation phenotyping by CAT monitored the activity of thrombin generation over time. Plasma levels of soluble thrombomodulin, tissue factor pathway inhibitor (TFPI) and von Willebrand factor (VWF) were measured as endothelial biomarkers.
RESULTS: Endogenous thrombin potential (ETP) in the absence of activated protein C (APC) tended to be increased in patients compared to controls (1769 versus 1656 nM.min; p=0.053). ETP was higher in the presence of APC 25 nM (ETP-APC) in patients (781 versus 494 nM.min; p=0.005). Five patients had ETP-APC higher than the 95th centile of controls. Other CAT parameters (lag time, peak thrombin and time to peak) were all consistent with some degree of hypercoagulability in patients. Regarding endothelial plasma biomarkers sTM was lower (28.4 versus 40.6 μg/l, p=0.0108) in patients; TFPI antigen and activity (respectively: 14.3 versus 10.5 μg/l, p=0.0167; 1.155 versus 1.070, p=0.0021) and VWF (1300 versus 976%, p=0.0108) were higher in patients.
CONCLUSION: We have demonstrated that at least some patients with iPAH have a hypercoagulable phenotype.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20888030     DOI: 10.1016/j.thromres.2010.08.020

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  12 in total

1.  Diagnostic dilemma in pulmonary arterial hypertension: idiopathic or chronic thromboembolic hypertension?

Authors:  U Canpolat; Ö Özeke; S Yılmaz; F N Başar; K Çağlı; Z Gölbaşı
Journal:  Herz       Date:  2013-12-04       Impact factor: 1.443

Review 2.  The intersection of protein disulfide isomerase and cancer associated thrombosis.

Authors:  Jack D Stopa; Jeffrey I Zwicker
Journal:  Thromb Res       Date:  2018-04       Impact factor: 3.944

3.  Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation.

Authors:  Jack D Stopa; Donna Neuberg; Maneka Puligandla; Bruce Furie; Robert Flaumenhaft; Jeffrey I Zwicker
Journal:  JCI Insight       Date:  2017-01-12

4.  Features associated with pulmonary arterial hypertension in Chinese hospitalized systemic lupus erythematosus patients.

Authors:  Shu-Zhen Xu; Xiang-Pei Li; Xiao-Mei Li; Zong-Wen Shuai; Rui-Xue Leng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2018-03-08       Impact factor: 2.980

5.  Expression of the Stp1 LMW-PTP and inhibition of protein CK2 display a cooperative effect on immunophilin Fpr3 tyrosine phosphorylation and Saccharomyces cerevisiae growth.

Authors:  M Marchetta; T Gamberi; S Sarno; F Magherini; G Raugei; G Camici; L A Pinna; A Modesti
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

Review 6.  Thrombosis, platelets, microparticles and PAH: more than a clot.

Authors:  Katie L Lannan; Richard P Phipps; R James White
Journal:  Drug Discov Today       Date:  2014-04-18       Impact factor: 7.851

Review 7.  Endothelial cells in the pathogenesis of pulmonary arterial hypertension.

Authors:  Colin E Evans; Nicholas D Cober; Zhiyu Dai; Duncan J Stewart; You-Yang Zhao
Journal:  Eur Respir J       Date:  2021-09-02       Impact factor: 33.795

Review 8.  Mechanisms of disease: pulmonary arterial hypertension.

Authors:  Ralph T Schermuly; Hossein A Ghofrani; Martin R Wilkins; Friedrich Grimminger
Journal:  Nat Rev Cardiol       Date:  2011-06-21       Impact factor: 32.419

Review 9.  Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?

Authors:  Kondababu Kurakula; Valérie F E D Smolders; Olga Tura-Ceide; J Wouter Jukema; Paul H A Quax; Marie-José Goumans
Journal:  Biomedicines       Date:  2021-01-09

Review 10.  Platelets, extracellular vesicles and coagulation in pulmonary arterial hypertension.

Authors:  Sarah Cullivan; Claire A Murphy; Luisa Weiss; Shane P Comer; Barry Kevane; Brian McCullagh; Patricia B Maguire; Fionnuala Ní Ainle; Sean P Gaine
Journal:  Pulm Circ       Date:  2021-06-04       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.